The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10660 malaria professionals are enjoying the free benefits of MalariaWorld today

Research: Inhibitory effect of deltorphin-II on development of malaria in Plasmodium berghei-infected mice

March 23, 2015 - 21:47 -- Bart G.J. Knols
Garasiya A. Ajitbhai, Prati P. Singh, Mukesh Kumar, Rajinder Singh, Vandana Dhiman
MWJ2015, 6, 3
Article type: 
Drug resistance has been one of the main obstacles in the fight against vector-borne infectious diseases. Among these diseases, malaria represents a serious public health challenge, mainly in the tropics, where vector-favourable climates are a crucial factor. Each of the various anti-malarial drugs currently used against this disease, such as quinolones, sulphonamides and artemisinins are inadequate and new strategies are required. Peptides are known to have a huge number of biological effects. Antimicrobial peptides (AMPs) have been proven to be effective against bacterial, fungal and viral infections. This study explored the effect of the peptide ‘deltorphin-II’ in Plasmodium berghei-infected mice. Mean percentage parasitaemia was calculated by studying infected erythrocytes after microscopic examination of 104 erythrocytes from infected mice on days 4, 7, 10, 14 and 21 after infection in all groups. Deltorphin-II shows maximum activity at a dose of 0.8 mg/kg/day from day 4 to day 21. Pre-treatment of infected mice with naltriben abrogates the deltorphin-II-mediated effect. Deltorphin-II inhibits the development of malaria, most probably via activation of the δ2 receptor.

PDF icon MWJ2015_6_3.pdf786.65 KB